Study Patient Characteristics Intervention End Point NCT00867113;  Phase II, non-randomized, open-label, multi-center Patients at significant risk for recurrence following complete resection of primary GIST. Imatinib mesylate 400 mg once per day by mouth for 5 years. Time to Recurrence Safety and Tolerability NCT01054911; Single institution, nonrandomized open label study   Sunitinib 37.5 mg p.o. daily for up to 12 weeks followed by surgical resection Safety and efficacy RR

Table 5: Current Adjuvant/Neoadjuvant Clinical Trials Ongoing in GIST [45-50]